Integrin α2β1 Represents a Prognostic and Predictive Biomarker in Primary Ovarian Cancer.
immune infiltrate
integrin α2β1
personalized medicine
predictive factor
primary ovarian cancer
prognostic factor
targeted therapy
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
12 Mar 2021
12 Mar 2021
Historique:
received:
24
01
2021
revised:
23
02
2021
accepted:
03
03
2021
entrez:
3
4
2021
pubmed:
4
4
2021
medline:
4
4
2021
Statut:
epublish
Résumé
Currently, the same first-line chemotherapy is administered to almost all patients suffering from primary ovarian cancer. The high recurrence rate emphasizes the need for precise drug treatment in primary ovarian cancer. Being crucial in ovarian cancer progression and chemotherapeutic resistance, integrins became promising therapeutic targets. To evaluate its prognostic and predictive value, in the present study, the expression of integrin α2β1 was analyzed immunohistochemically and correlated with the survival data and other therapy-relevant biomarkers. The significant correlation of a high α2β1-expression with the estrogen receptor alpha (ERα;
Identifiants
pubmed: 33809043
pii: biomedicines9030289
doi: 10.3390/biomedicines9030289
pmc: PMC7999332
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Bundesministerium für Wissenschaft und Forschung
ID : FKZ 16EX1021N
Références
J Clin Oncol. 2018 Jul 10;36(20):2105-2122
pubmed: 29846122
J Clin Oncol. 2019 Sep 20;37(27):2460-2471
pubmed: 31403857
Theranostics. 2011 Feb 17;1:154-88
pubmed: 21547158
Invest New Drugs. 2016 Jun;34(3):329-37
pubmed: 27039386
Cancers (Basel). 2017 Jul 08;9(7):
pubmed: 28698469
Asian Pac J Cancer Prev. 2013;14(6):3891-5
pubmed: 23886203
Semin Cancer Biol. 2015 Dec;35:145-53
pubmed: 26297892
Oncogene. 2011 Sep 1;30(35):3766-83
pubmed: 21478904
Ann Oncol. 2019 May 1;30(5):672-705
pubmed: 31046081
Oncogene. 2014 Mar 27;33(13):1658-69
pubmed: 23604127
Ann Oncol. 2017 Apr 1;28(4):727-732
pubmed: 27993805
Cancers (Basel). 2017 Aug 23;9(9):
pubmed: 28832494
Cancer Cell. 2011 Jun 14;19(6):715-27
pubmed: 21665146
Matrix Biol. 2000 Aug;19(4):319-23
pubmed: 10963992
Cancers (Basel). 2019 Jul 12;11(7):
pubmed: 31336983
Clin Cancer Res. 2005 May 1;11(9):3433-8
pubmed: 15867245
Lancet Oncol. 2013 Aug;14(9):853-62
pubmed: 23845225
Surg Oncol Clin N Am. 2019 Jul;28(3):447-464
pubmed: 31079799
Lancet Oncol. 2016 Dec;17(12):e542-e551
pubmed: 27924752
Clin Transl Oncol. 2014 Jul;16(7):668-74
pubmed: 24248895
Biomedicines. 2021 Jan 08;9(1):
pubmed: 33435590
Gynecol Oncol. 2020 Oct;159(1):277-284
pubmed: 32698955
J Biol Chem. 2005 Nov 4;280(44):36873-82
pubmed: 16103112
Clin Cancer Res. 2011 Jan 1;17(1):193-200
pubmed: 21208908
J Natl Compr Canc Netw. 2019 Aug 1;17(8):896-909
pubmed: 31390583
Cancers (Basel). 2019 Aug 26;11(9):
pubmed: 31455033
Int J Clin Exp Pathol. 2015 Oct 01;8(10):12802-10
pubmed: 26722470
Biomolecules. 2019 Nov 26;9(12):
pubmed: 31779287
Cancer Res. 2008 Apr 1;68(7):2329-39
pubmed: 18381440
J Carcinog. 2007 Jun 14;6:11
pubmed: 17567918
Gynecol Oncol. 2014 Feb;132(2):455-61
pubmed: 24378876
Nat Rev Cancer. 2018 Sep;18(9):533-548
pubmed: 30002479
J Cell Sci. 2006 Oct 1;119(Pt 19):3901-3
pubmed: 16988024
Oncogene. 2001 Aug 16;20(36):4995-5004
pubmed: 11526484
Clin Cancer Res. 2000 Jan;6(1):96-101
pubmed: 10656437
Front Genet. 2020 Jul 17;11:705
pubmed: 32765584
Cell Adh Migr. 2013 May-Jun;7(3):251-61
pubmed: 23563505
Cancers (Basel). 2019 Oct 21;11(10):
pubmed: 31640297
Cancer. 2009 Mar 15;115(6):1234-44
pubmed: 19189349
Cell. 2002 Sep 20;110(6):673-87
pubmed: 12297042
Cancers (Basel). 2019 Aug 21;11(9):
pubmed: 31438626
Am J Pathol. 1990 Jul;137(1):113-20
pubmed: 2164774
Oncotarget. 2017 Feb 28;8(9):15621-15631
pubmed: 28152503
Cancer Res. 2007 Jan 15;67(2):659-64
pubmed: 17234776
Nat Med. 1999 Jun;5(6):662-8
pubmed: 10371505
Biochim Biophys Acta Mol Cell Res. 2020 May;1867(5):118663
pubmed: 31987794
J Biomed Res. 2016 May;30(3):217-24
pubmed: 27533932
Cell Biol Int. 2020 Feb;44(2):610-620
pubmed: 31743535
Ann Oncol. 2017 Nov 1;28(suppl_8):viii51-viii56
pubmed: 29232464
Int J Mol Sci. 2016 Dec 06;17(12):
pubmed: 27929432
Sci Rep. 2019 Nov 14;9(1):16832
pubmed: 31728045
Circ Res. 2001 Dec 7;89(12):1104-10
pubmed: 11739274
Virchows Arch. 2010 Sep;457(3):299-307
pubmed: 20665045
Am J Pathol. 2010 Sep;177(3):1053-64
pubmed: 20651229
Oncotarget. 2018 Apr 27;9(32):22832-22849
pubmed: 29854318
Onco Targets Ther. 2018 Mar 29;11:1787-1799
pubmed: 29636624
J Natl Cancer Inst. 2014 Apr 03;106(5):
pubmed: 24700801